ys-49 and Thrombosis

ys-49 has been researched along with Thrombosis* in 1 studies

Other Studies

1 other study(ies) available for ys-49 and Thrombosis

ArticleYear
Antithrombotic effects of YS-49 and YS-51--1-naphthylmethyl analogs of higenamine.
    Thrombosis research, 2001, Nov-15, Volume: 104, Issue:4

    The antiplatelet and antithrombotic effects of YS-49 and YS-51--l-naphthylmethyl analogs of higenamine, which is a benzyl-tetrahydroisoquinoline alkaloid isolated from Aconitum japonicum (Ranunculaceae)--were investigated. YS-49 and YS-51 showed inhibitory activities to both human and rat platelet aggregation induced by ADP, collagen and epinephrine. They were more inhibitory to epinephrine-induced aggregation (IC(50); 3.4 and 1.7 microM of YS-49, and 6.0 and 6.3 microM of YS-51 to human and rat platelets, respectively) than ADP- or collagen-induced aggregation. The antithrombotic effects of YS-49 and YS-51 were also observed in both mouse acute thrombosis model and rat arterio-venous shunt (AV shunt) model. The oral administration of YS-49 and YS-51 (50 or 100 mg/kg) increased the recovery rates from the acute thrombotic challenge in mice and lowered the weight of thrombus formed inside the AV shunt tube in rats.

    Topics: Alkaloids; Animals; Disease Models, Animal; Fibrinolytic Agents; Humans; Inhibitory Concentration 50; Isoquinolines; Mice; Mice, Inbred ICR; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines; Thrombosis; Treatment Outcome

2001